Downer EDI vs Cochlear: ASX Investors Weigh Value Case for DOW and COH in 2026

The Quick Take

• Australian investors are comparing valuation cases for Downer EDI (ASX:DOW) and Cochlear (ASX:COH), two ASX-listed companies in different sectors with contrasting growth and risk profiles
• Cochlear, a global leader in cochlear hearing implants, commands a premium valuation reflecting healthcare earnings durability and global medical device market expansion
• Downer EDI, an infrastructure and services company, trades at a discount to Cochlear on most valuation metrics, reflecting its lower-margin contract services model and higher execution risk

The comparison between Downer EDI (infrastructure services) and Cochlear (medical devices) highlights growing interest among Australian retail investors in cross-sector value analysis for ASX-listed companies. Cochlear holds a dominant position in the cochlear implant market globally, benefiting from aging demographics, expanded hearing health reimbursement, and a recurring revenue stream from processor upgrades and accessories. Downer EDI operates in the infrastructure services sector with exposure to government infrastructure spending in Australia and New Zealand, a sector where contract execution risk and working capital intensity tend to compress valuation multiples relative to asset-light medical device peers like Cochlear.

The divergent sectoral dynamics between Cochlear and Downer EDI mean they appeal to different investor profiles: Cochlear suits growth-oriented investors seeking global earnings exposure with a healthcare premium, while Downer EDI may attract value investors seeking exposure to Australia's infrastructure buildout pipeline at a lower entry multiple. For portfolio construction, both names offer ASX market exposure but with minimal correlation between their earnings drivers, making them complementary rather than competitive holdings. Cochlear's ASX premium reflects global comparative advantage in a specialized medical device category, while Downer's value case depends on margin recovery and infrastructure spend cycle timing.

Watch for Cochlear's next half-year results showing global unit volume growth in emerging markets, which remains the primary upside catalyst for the stock. For Downer EDI, infrastructure contract win announcements and any improvement in net margin guidance are the key signals. The macro variable is Australian government infrastructure budget allocation: sustained federal and state infrastructure spending directly supports Downer's revenue pipeline and could narrow the valuation gap between the two names if Downer's execution consistency improves in the second half of 2026.

Synthesized from 1 source.